Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
04/2003
04/02/2003CN1104191C Method and apparatus for treating body fluid
04/01/2003WO2002029054A1 Novel protein, process for producing the same and use thereof
04/01/2003US6541669 Multibinding amine compounds which are beta 2 adrenergic receptor agonists useful in treatment and prevention of respiratory diseases such as asthma, bronchitis
04/01/2003US6541634 Process for preparing growth hormone secretagogues
04/01/2003US6541623 Sepsis shock therapy; rheumatic diseases; antiinflammatory agents; nucleotide sequence detector
04/01/2003US6541621 Hypoxia inducible promoter
04/01/2003US6541620 Antagonist for tumor necrosis factor; antiinflammatory agents; rheumatic diseases
04/01/2003US6541619 Genetic engineering; transforming Escherichia culture product; anticancer agent
04/01/2003US6541616 Exterior membrane; nucleotide sequence; induction immunology response
04/01/2003US6541615 SIRP proteins and uses thereof
04/01/2003US6541610 Genetic engineering; drugs
04/01/2003US6541607 Sublancin lantibiotic produced by Bacillus subtilis 168
04/01/2003US6541605 Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
04/01/2003US6541604 Genetic engineering
04/01/2003US6541603 Genes and genetic elements associated with sensitivity to platinum-based drugs
04/01/2003US6541467 And at P1 have a six-membered heterocyclic ring having two ring nitrogen ring atoms and the remainder of the ring atoms carbon atoms.
04/01/2003US6541466 Such as 1-(N'-(3,5-difluorophenylacetyl)-L-alaninyl)-aminodibenzosuberane; for treatment of Alzheimer's disease
04/01/2003US6541459 Soluble herpesvirus glycoprotein complex vaccine
04/01/2003US6541457 Mammalian IAP gene family, primers, probes and detection methods
04/01/2003US6541455 Applying to area of body having ectoparasites a composition comprising non-volatile surfactants, polar organic compounds, non-volatile fatty alcohols, and non-volatile fatty esters, for a time sufficient to trigger immersion reflex, drying
04/01/2003US6541454 Phosphonates, biphosphonates and pharmaceutical compositions containing them
04/01/2003US6541453 Peptide derivatives
04/01/2003US6541452 Brain-associated inhibitor of tissue-type plasminogen activator
04/01/2003US6541450 Parathyroid hormone analogues for the treatment of osteoporosis
04/01/2003US6541449 Administering dosage of hemoglobins; transferring oxygen to tissues
04/01/2003US6541447 Wound healing composition and method for use thereof
04/01/2003US6541256 Growth medium for human corneal endothelial cells
04/01/2003US6541254 Glycosylation variants of iduronate 2-sulfatase
04/01/2003US6541253 Diagnostics and therapy of diseases associated with HHV-8 infections
04/01/2003US6541252 Human kinases and polynucleotides encoding the same
04/01/2003US6541248 Genome comprising nucleotide sequence encoding an anti-sense RNA or ribozyme; cleavage of a second nucleotide sequence which encodes a polypeptide; use in gene therapy
04/01/2003US6541244 Suppressor of cytokine signaling (SOCS)-3 promoter and methods for its use in genetic therapy in humans
04/01/2003US6541230 Using polyurethane, cholinesterases, and reactivation compounds; efficiency
04/01/2003US6541220 Novel parathyroid hormone (PTH), parathyroid hormone related protein (PTHrP), receptors (PTH1R and PTH3R) isolated from zebrafish; vectors, host cells, recombinant methods for producing; use in identifying receptor agonists, antagonists
04/01/2003US6541219 Therapeutic Gene
04/01/2003US6541218 Isolated nucleic acid encoding title protein; genetic engineering; use in diagnosis and treatment of Type B Niemann-Pick Disease
04/01/2003US6541217 Polypeptide for use in the treatment of cancer and hematopoietic defects
04/01/2003US6541214 N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
04/01/2003US6541212 Anticancer agents
04/01/2003US6541208 Measurement of Monocyte Chemoattractant Protein (MCP-1); HIV transactivator protein TAT; astrocytes; antagonists and inhibitors; use in treatment, prevention of HIV associated dementia
04/01/2003US6541036 Placing tumor cells in culture in vitro or ex vivo supplemented with pro-apoptotic agent, transferring tumor cells into diffusion chamber, inserting chamber into human for therapeutically effective time
04/01/2003US6541033 Thermosensitive biodegradable hydrogels for sustained delivery of leptin
04/01/2003US6541026 Nutritional composition, methods of producing said composition and methods of using said composition
04/01/2003US6541020 An antiviral agent consists of a polymer material that forms a hydrogel at physiological temperatures, and a polypeptide having a specific amino acid sequence
04/01/2003US6541013 A Shiga-toxin polypeptide is administered in an amount effective to suppress bovine leukemia-related lymphocyte cell proliferation
04/01/2003US6541008 Vascular endothelial growth factor-like protein from orf viruses binds and activates mammalian VEGF receptor-2, and uses thereof
04/01/2003US6541002 Rendering a polypeptide capable of binding with virion by altering the polypeptide such that the altered polypeptide comprises a Vpr-binding region having specific amino acid sequence
04/01/2003US6540999 Administering to patient an antigen, a multivalent conjugate of multiple Lewisx antigen-containing oligosaccharides crosslinked to a carrier molecule and an adjuvant to stimulate a specific antibody response to above antigen
04/01/2003US6540993 Method of treating inflammatory bowel disease using a topical formulation of IL-11
04/01/2003US6540992 Elk ligand (Elk-L) where elk is a member of the tyrosine kinase receptor family; protects against excitotoxicity, especially of the hipocammpal neurons
04/01/2003US6540983 A drug selected from an insulin analog, and/or amylin, a fluid propellant carrier, and a stabilizer comprising water added in addition to nascent formulation water; treating diabetes; inhalers
04/01/2003US6540982 Medical aerosol formulation
04/01/2003US6540715 Method and device for in-situ formulation of a medicinal solution for parenteral application
04/01/2003CA2424777A1 Novel protein, process for producing the same and use thereof
04/01/2003CA2235951C Novel uses of mammalian ctla-8 and related reagents
04/01/2003CA2102129C Growth hormone antagonists
04/01/2003CA2043741C Endothelin antagonistic peptide derivatives
04/01/2003CA1341426C Process for the manufacture of thrombin inhibitors
03/2003
03/28/2003CA2405342A1 Methods of treatment and kits comprising a growth hormone secretagogue
03/28/2003CA2404723A1 Methods related to the a-c repeat z-sequence upstream from the aldose reductase gene
03/28/2003CA2404045A1 Use of coagulation factor vii-activating protease for the prophylaxis and therapy of vasoproliferative disorders
03/28/2003CA2398030A1 Therapeutic agents for achondroplasia
03/27/2003WO2003029411A2 Novel cyclooxygenase variants and methods of use
03/27/2003WO2003025579A2 Use of heart fatty acid binding protein
03/27/2003WO2003025571A1 Diagnostic markers for ischemia
03/27/2003WO2003025542A2 Immune response associated proteins
03/27/2003WO2003025541A2 Methods for treating multiple sclerosis
03/27/2003WO2003025228A1 Methods and compositions for treating hcap associated diseases
03/27/2003WO2003025225A2 Pthr1 gene polymorphisms
03/27/2003WO2003025200A2 Methods of using 22417, a novel human aminoprotease family member
03/27/2003WO2003025199A2 Mid 4460, a human tyrosine phosphatase family member and uses therefor
03/27/2003WO2003025197A2 Mutant sh3-binding protein compositions and methods
03/27/2003WO2003025195A2 Nucleic acid constructs for the delivery of polynucleotides into dna-containing organelles,and uses thereof
03/27/2003WO2003025179A1 Novel polypeptide, dna thereof and use of the same
03/27/2003WO2003025178A1 Novel protein and dna thereof
03/27/2003WO2003025173A1 Novel antisense oligonucleotide derivatives to hepatitis c virus
03/27/2003WO2003025171A2 Modulation of retinoic acid receptor gene expression and therapeutic uses thereof
03/27/2003WO2003025168A1 Novel protein and dna thereof
03/27/2003WO2003025150A2 Lipid-associated molecules
03/27/2003WO2003025147A2 Novel polynucleotides and proteins encoded thereby
03/27/2003WO2003025144A2 Antisense modulation of ksr expression
03/27/2003WO2003025142A2 Novel nucleic acids and secreted polypeptides
03/27/2003WO2003025140A2 Transductin-1 and transductin-2 and applications to hereditary deafness
03/27/2003WO2003025135A2 Genes associated with malignant neoplasms
03/27/2003WO2003025131A2 Protein modification and maintenance molecules
03/27/2003WO2003025130A2 Receptors and membrane-associated proteins
03/27/2003WO2003025129A2 Neurotransmission-associated proteins
03/27/2003WO2003025121A2 Igf-binding protein-derived peptide or small molecule
03/27/2003WO2003025120A2 Clasp membrane proteins
03/27/2003WO2003025119A2 Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies
03/27/2003WO2003025015A2 A soluble toll-like receptor
03/27/2003WO2003025014A2 Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies
03/27/2003WO2003025010A2 Human delta-n p73 molecules and uses thereof
03/27/2003WO2003025007A2 Purified polypeptides involved in membrane biosynthesis
03/27/2003WO2003025001A1 Multiple antigen peptides (map) as antidotes against snake neurotoxin intoxication
03/27/2003WO2003025000A2 Peptides capable of modulating immune response
03/27/2003WO2003024998A1 T cell epitopes of the cyn d 1 allergen from bermuda grass pollen
03/27/2003WO2003024997A1 Telomerase inhibitory peptides and uses thereof
03/27/2003WO2003024996A2 Antibacterial macrocycles
03/27/2003WO2003024995A1 Molecules that block viral infectivity and methods of use thereof
1 ... 1876 1877 1878 1879 1880 1881 1882 1883 1884 1885 1886 1887 1888 1889 1890 1891 1892 1893 1894 1895 1896 ... 3163